227 related articles for article (PubMed ID: 12782969)
21. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
22. [Cytochrome P450*2D6 gene polymorphism in Chinese population].
Tao E; Liu Z; Chen B; Pan X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Feb; 15(1):34-7. PubMed ID: 9456373
[TBL] [Abstract][Full Text] [Related]
23. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
24. Association of CYP2D6 genotypes and personality traits in healthy individuals.
Kirchheiner J; Lang U; Stamm T; Sander T; Gallinat J
J Clin Psychopharmacol; 2006 Aug; 26(4):440-2. PubMed ID: 16855473
[No Abstract] [Full Text] [Related]
25. CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C.
Hijikata M; Miyakawa H; Matsushita M; Kako M; Ohta Y; Mishiro S
Biochem Biophys Res Commun; 2000 Apr; 270(3):922-6. PubMed ID: 10772926
[TBL] [Abstract][Full Text] [Related]
26. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
[TBL] [Abstract][Full Text] [Related]
27. Association between angiotensin I-converting enzyme insertion/deletion gene functional polymorphism and novelty seeking personality in healthy females.
Shimizu E; Hashimoto K; Ohgake S; Koizumi H; Okamura N; Koike K; Fujisaki M; Iyo M
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):99-103. PubMed ID: 16236416
[TBL] [Abstract][Full Text] [Related]
28. Association study between a functional polymorphism of FK506-binding protein 51 (FKBP5) gene and personality traits in healthy subjects.
Shibuya N; Suzuki A; Sadahiro R; Kamata M; Matsumoto Y; Goto K; Hozumi Y; Otani K
Neurosci Lett; 2010 Nov; 485(3):194-7. PubMed ID: 20849924
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphism of CYP2D6 in patients with cardiovascular disease -- a cohort study.
Teh LK; Zilfalil BA; Marina I; Rosemi BS; Ismail R
J Clin Pharm Ther; 2004 Dec; 29(6):559-64. PubMed ID: 15584944
[TBL] [Abstract][Full Text] [Related]
30. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
31. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms.
van der Padt A; van Schaik RH; Sonneveld P
Neth J Med; 2006 May; 64(5):160-2. PubMed ID: 16702617
[TBL] [Abstract][Full Text] [Related]
32. Genetics and personality traits in patients with social anxiety disorder: a case-control study in South Africa.
Lochner C; Hemmings S; Seedat S; Kinnear C; Schoeman R; Annerbrink K; Olsson M; Eriksson E; Moolman-Smook J; Allgulander C; Stein DJ
Eur Neuropsychopharmacol; 2007 Apr; 17(5):321-7. PubMed ID: 16899354
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 and CYP1A1 mutations in the Turkish population.
Aydin M; Hatirnaz O; Erensoy N; Ozbek U
Cell Biochem Funct; 2005; 23(2):133-5. PubMed ID: 15648054
[TBL] [Abstract][Full Text] [Related]
34. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
35. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.
Zateyshchikov DA; Minushkina LO; Brovkin AN; Savel'eva EG; Zateyshchikova AA; Manchaeva BB; Nikitin AG; Sidorenko BA; Nosikov VV
Fundam Clin Pharmacol; 2007 Aug; 21(4):437-43. PubMed ID: 17635183
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 in the brain: genotype effects on resting brain perfusion.
Kirchheiner J; Seeringer A; Godoy AL; Ohmle B; Maier C; Beschoner P; Sim EJ; Viviani R
Mol Psychiatry; 2011 Mar; 16(3):237, 333-41. PubMed ID: 20368706
[TBL] [Abstract][Full Text] [Related]
37. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
38. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs.
Savino M; Seripa D; Gallo AP; Garrubba M; D'Onofrio G; Bizzarro A; Paroni G; Paris F; Mecocci P; Masullo C; Pilotto A; Santini SA
Clin Lab; 2011; 57(11-12):887-93. PubMed ID: 22239018
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
